Filing Details
- Accession Number:
- 0001209191-20-050225
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-11 21:00:11
- Reporting Period:
- 2020-09-10
- Accepted Time:
- 2020-09-11 21:00:11
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1478320 | Adaptive Biotechnologies Corp | ADPT | Biological Products, (No Disgnostic Substances) (2836) | 270907024 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1780773 | Lance Baldo | C/O Adaptive Biotechnologies Corp. Suite 200 Seattle WA 98102 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-09-10 | 18 | $7.80 | 18 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-09-10 | 18 | $40.00 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-09-11 | 4,149 | $7.80 | 4,149 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-09-11 | 4,149 | $40.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-09-10 | 18 | $0.00 | 18 | $7.80 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-09-11 | 4,149 | $0.00 | 4,149 | $7.80 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
429,149 | 2029-05-06 | No | 4 | M | Direct | |
425,000 | 2029-05-06 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.
- The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.